Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00345358
First received: June 27, 2006
Last updated: September 6, 2012
Last verified: August 2012

June 27, 2006
September 6, 2012
September 2006
November 2007   (final data collection date for primary outcome measure)
Concentrations of antibodies against vaccine pneumococcal serotypes [ Time Frame: 1 month after the administration of the primary or the full vaccination course with GSK Biologicals' 10-valent pneumococcal conjugate vaccine ] [ Designated as safety issue: No ]
Post dose 3, 2, 1 (depending on group): anti-pneumo Ab conc
Complete list of historical versions of study NCT00345358 on ClinicalTrials.gov Archive Site
  • Opsonophagocytic activity against vaccine pneumococcal serotypes [ Time Frame: 1 month after the administration of the primary or the full vaccination course, with GSK Biologicals' 10-valent pneumococcal conjugate vaccine ] [ Designated as safety issue: No ]
  • Concentrations of antibodies against cross-reactive pneumococcal serotypes [ Time Frame: 1 month after the administration of the primary or the full vaccination course, with GSK Biologicals' 10-valent pneumococcal conjugate vaccine ] [ Designated as safety issue: No ]
  • Opsonophagocytic activity against cross-reactive pneumococcal serotypes. [ Time Frame: 1 month after the administration of the primary or the full vaccination course, with GSK Biologicals' 10-valent pneumococcal conjugate vaccine ] [ Designated as safety issue: No ]
  • Concentrations of antibodies against protein D. [ Time Frame: 1 month after the administration of the primary or the full vaccination course, with GSK Biologicals' 10-valent pneumococcal conjugate vaccine ] [ Designated as safety issue: No ]
  • Concentrations of antibodies against vaccine pneumococcal serotypes. [ Time Frame: Before and one month after the booster dose with GSK Biologicals' 10-valent pneumococcal conjugate vaccine for the < 6 Mo and 7-11 Mo groups ] [ Designated as safety issue: No ]
  • Opsonophagocytic activity against vaccine pneumococcal serotypes [ Time Frame: Before and one month after the booster dose with GSK Biologicals' 10-valent pneumococcal conjugate vaccine for the < 6 Mo and 7-11 Mo groups ] [ Designated as safety issue: No ]
  • Concentrations of antibodies against cross-reactive pneumococcal serotypes [ Time Frame: Before and one month after the booster dose with GSK Biologicals' 10-valent pneumococcal conjugate vaccine for the < 6 Mo and 7-11 Mo groups ] [ Designated as safety issue: No ]
  • Opsonophagocytic activity against cross-reactive pneumococcal serotypes [ Time Frame: Before and one month after the booster dose with GSK Biologicals' 10-valent pneumococcal conjugate vaccine for the < 6 Mo and 7-11 Mo groups ] [ Designated as safety issue: No ]
  • Concentrations of antibodies against protein D. [ Time Frame: Before and one month after the booster dose with GSK Biologicals' 10-valent pneumococcal conjugate vaccine for the < 6 Mo and 7-11 Mo groups ] [ Designated as safety issue: No ]
  • Anti-diphtheria and anti-tetanus toxoids, anti-PRP, anti-pertussis, anti-HBs antibody concentrations and anti-polio type 1, 2 and 3 titres. [ Time Frame: 1 month after the administration of the primary vaccination course, before & 1 mth after the booster dose with GSK Biologicals' DTPa-IPV/Hib vaccine when co-administered with GSK Biologicals' 10-valent pneumococcal conjugate vaccine in the < 6 Mo gr ] [ Designated as safety issue: No ]
  • Booster vaccine response to pertussis [ Time Frame: One month after the booster dose in the < 6 Mo group ] [ Designated as safety issue: No ]
  • Occurrence of solicited local symptoms [ Time Frame: Within 4 days after each vaccination. ] [ Designated as safety issue: Yes ]
  • Occurrence of solicited general symptoms [ Time Frame: Within 4 days after each vaccination. ] [ Designated as safety issue: Yes ]
  • Occurrence of unsolicited adverse events [ Time Frame: Within 31 days after each vaccination. ] [ Designated as safety issue: Yes ]
  • Occurrence of serious adverse events. [ Time Frame: Throughout the whole study period ] [ Designated as safety issue: Yes ]
  • Pre & post boost: immuno of pneumo vaccine
  • Immuno of co-admin vaccine
  • Solicited/unsolicited AEs & SAEs
Not Provided
Not Provided
 
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Evaluate Immunogenicity, Safety & Reactogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-dose Primary Immunization in Children Before 6 mo of Age

The purpose of this phase IIIb study is to determine whether children who have not received a 3-dose primary vaccination with the pneumococcal conjugate vaccine before their 6 months of age, can receive the vaccine as part of a catch-up immunization schedule. The immunogenicity, safety and reactogenicity of GSK Biologicals' pneumococcal conjugate vaccine will be evaluated for four different age groups with different schedules:

< 6 months of age group: 3-dose primary vaccination + a booster dose. 7 to 11 months of age group: 2-dose primary vaccination + a booster dose. 12 to 23 months of age group: 2-dose vaccination; no booster dose. 24 months to 5 years of age group: 1-dose vaccination; no booster dose. Children below 6 months of age will receive concomitantly a DTPa-IPV/Hib vaccine.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Pneumococcal Disease
  • Streptococcus Pneumoniae Vaccines
  • Biological: Pneumococcal conjugate vaccine GSK1024850A.
    1, 2, 3 or 4 Intramuscular injections, depending on age group
  • Biological: Infanrix IPV/Hib
    4 intramuscular injections
    Other Name: DTPa-IPV/Hib
  • Active Comparator: <6 Mo
    Children of 9-12 weeks of age at the time of first vaccination receiving 3-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix IPV/Hib) at 3-4-5 months of age and a booster dose at 12-15 months of age.
    Interventions:
    • Biological: Pneumococcal conjugate vaccine GSK1024850A.
    • Biological: Infanrix IPV/Hib
  • Experimental: 7-11 Mo
    Children between 7 to 11 months of age at the time of first vaccination receiving 2-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A with at least 4 weeks interval and a booster dose at 12-15 months
    Intervention: Biological: Pneumococcal conjugate vaccine GSK1024850A.
  • Experimental: 12-23 Mo
    Children between 12 to 23 months of age at the time of first vaccination receiving 2-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A with at least 8 weeks interval
    Intervention: Biological: Pneumococcal conjugate vaccine GSK1024850A.
  • Experimental: >=24 Mo
    Children between 24 months to 5 years of age at the time of first vaccination receiving single dose of pneumococcal conjugate vaccine GSK1024850A
    Intervention: Biological: Pneumococcal conjugate vaccine GSK1024850A.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
November 2007
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female between, and including

    • 9-12 weeks of age at the time of first vaccination for the <6 Mo group.
    • 7-11 months of age at the time of first vaccination for the 7-11 Mo group.
    • 12-23 months of age at the time of first vaccination for the 12-23 Mo group.
    • 24 months to 5 years at the time of first vaccination for the >= 24 Mo group.
  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol
  • Written informed consent obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Born after a gestation period between 36 and 42 weeks.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the entire study period for each age-group.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before and ending one month after each dose of vaccine(s).
  • Previous vaccination against S. pneumoniae.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease.
  • Acute disease at the time of enrolment.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
  • A family history of congenital or hereditary immunodeficiency.
  • Major congenital defects or serious chronic illness.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the entire study period.
Both
9 Weeks to 60 Months
Yes
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT00345358
107058
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP